In-depth proteomic analysis of non-small cell lung cancer to discover molecular targets and candidate biomarkers
Advances in proteomic analysis of human samples are driving critical aspects of biomarker discovery and the identification of molecular pathways involved in disease etiology. Toward that end, in this report we are the first to utilize a standardized shotgun proteomic analysis method for in-depth tissue protein profiling of the two major subtypes of non-small cell lung cancer (NSCLC) and normal lung tissues. We identified 3621 proteins from the analysis of pooled human samples of squamous cell carcinoma, adenocarcinoma and control specimens. In addition to proteins previously shown to be implicated in lung cancer, we have identified multiple new proteins of potential interest as therapeutic targets or diagnostic biomarkers, including some that were not identified by transcriptome profiling. Up-regulation of these proteins was confirmed by multiple reaction monitoring mass spectrometry (LC-MRM-MS). This proteomic technology platform allows deep mining of lung tumor proteomes, enabling the identification of novel, previously undetected biomarker candidates and potential targets for therapy.
There are currently no biomarkers annotated for this protocol.